A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing,
parallel-group, multicenter study designed to evaluate the efficacy and safety of
suvecaltamide for the treatment of moderate to severe residual tremor in adult participants
with Parkinson's disease (PD). The target population represents participants who have tremor
that is not adequately controlled by PD medications and that interferes with their activities
of daily living (ADL) and/or with their performance of tasks.